Following Thyroid Nodules with Ultrasound

benign_nodule_thyroid_ultrasoundFollowing Thyroid Nodules with Ultrasound by Jeffrey Dach MD

Don’t Fall for the thyroid nodule trap.

Yesterday, a mother and her 18 year old daughter came into the office for the daughter’s low thyroid condition.  She had just come from an endocrinologist’s office where they discovered a small thyroid nodule during a thyroid ultrasound exam.  The young lady was not given thyroid medication, and instead told to return in 6 months to follow the nodule.  The mother asked me if we also do thyroid ultrasound in my office.  I explained we follow many thyroid nodules with serial ultrasound exams done at the hospital outpatient imaging center.  All of the nodules have decreased in size, and none have ever required surgery.  Don’t fall for the thyroid nodule trap.  Here is a patient who did fall for the thyroid nodule trap.  After a thyroid ultrasound, she underwent biopsy for a small nodule and then agreed to thyroidectomy and radiation therapy, treatments that are overly aggressive and probably unnecessary.

A 36 Year Old Female With Hypothyroidism After Thyroidectomy For Incidentaloma (Papillary Thyroid Cancer)

Lisa was a 36 year old model and actress who had thyroidectomy for papillary thyroid cancer.  After the surgery,  she has severe fatigue, muscle pain, hair loss, and dry skin. The small dose of Synthroid (levothyroxine) prescribed by her endocrinologist is not helping to relieve her sympotoms of a low thyroid condition.

Upper left image thyroid nodule courtesy of drtbalu’s otolaryngology resources.

Finding Thyroid Nodules

Thyroid Gland in Neck

How did she end up with t thyroidectomy? Her family doctor palpated her thyroid gland and was not sure if he felt a nodule, so he ordered a thyroid ultrasound which showed a small nodule 9 mm in size.  The doctor then  recommended ultrasound guided needle biopsy, “just to be sure”.  The biopsy report came back as “papillary carcinoma of the thyroid”.

Upper Left Image: Thyroid Gland Courtesy Wikimedia Commons

Lisa is Told She Has Thyroid Cancer

As you can imagine, Lisa was distraught to learn she had thyroid cancer. “Not to worry”, said her doctor,“You have an excellent prognosis and a high likelihood for cure after surgery followed by radioactive Iodine treatment.”

Video_Assisted_ThyroidectomyLisa Undergoes Surgery and Radiation – Complete Thyroidectomy

Grateful to her doctors, Lisa underwent the surgery and radiation. Since the neck surgeon removed the entire thyroid gland, Lisa takes thyroid medication every day. She also returns for screening tests every year to check for recurrent cancer.

Above Image: Video Assisted Thyroidectomy, courtesy of wikimedia commons.

Adverse Effects of Treatment

Unfortunately, Lisa was not spared the adverse effects of her treatment. The surgery had disturbed her recurrent laryngeal nerve, leaving her with a chronic hoarseness, cough and voice change. The surgery also removed the parathyroid glands leaving her at risk for osteoporosis. The radioactive iodine treatment caused salivary gland damage, leaving her with a chronic dry mouth and bad taste. The radioactive Iodine also carried an increased generalized cancer risk over her lifetime, and of course, detrimental effect on fertility in the future when Lisa decides to have a family.

Switching from Synthroid to Natural Thyroid

I explained to Lisa that her symptoms of hypothyroidism were caused by inadequate dosage of thyroid medication.  Her Synthroid dosage was insufficient.   We switched Lisa to Natural dessicated thyroid medication, a far better choice in medication.  Lisa’s medication  was switched to Nature-Throid from RLC labs.  She was also given Iodine supplementation.  Three weeks later, Lisa called in to report a dramatic improvement, with relief of chronic fatigue, and better energy.

A Cancer with No Biological Significance

Part of my job at the hospital as an interventional radiologist was to perform ultrasound needle biopsies of thyroid nodules.  Most of these were cases sent to the hospital by primary care doctors and endocrinologists.  Thyroid nodules are common, found in 60% of the population.   Most nodules are benign, however, occasionally the biopsy shows a small papillary carcinoma, a relatively benign tumor with excellent prognosis of no clinical significance.(3)  In spite of the benign nature of these tumors, conventional medicine treats them aggressively with thyroidectomy and radiation therapy (I-131 capsule).

thyroid_sonogramLeft image: Thyroid sonogram transverse image. 1=right carotid artery, 2=right thyroid gland, 3=trachea, 4=left thyroid gland, 5=left carotid artery. Courtesy of Wikimedia Commons.

A Frustrated Radiologist Says : Turn Off the Ultrasound Machines

An exasperated radiologist, John J. Cronan, MD says in the June 2008 issue of Radiology we should “turn off the ultrasound machines”. Cronan questions this entire medical enterprise of detecting thyroid nodules, and small cancers with ultrasound guided biopsy.(2)

“From the patient perspective, we have hung the psychologic stigma of cancer on these patients and the dependency for daily thyroid supplementation…We accept all these consequences to control a cancer with a 99% 10-year survival.” quote Dr Cronen.(2)

A Normal Finding

Dr Harach says occult papillary carcinoma of the thyroid is a “normal finding” in Finland, and does not cause biologically significant disease.(9)(43)

Dr. Louise Davies agrees with Dr Harach, and says in JAMA, “papillary cancers smaller than 1 cm could be classified as a normal finding”.(5)

Our Quixotic Approach to Thyroid Nodules

Don_Quixote_windmill_thyroid_nodulesKeith Heller, MD, a neck surgeon who operated on 1,000 cases of thyroid cancer over a 28 year career, addressed his colleagues in a medical meeting saying:(4)

“I do not believe that this epidemic of (thyroid cancer) is real. It is due to …the increasing use of ultrasound-guided needle biopsy of thyroid nodules. We may be diagnosing and treating cancers that have no clinical significance…We have embarked on a quixotic quest to rid our patients of microscopic and probably clinically unimportant thyroid cancer…. We are performing far too many unnecessary thyroidectomies. “(4)

Above Left image: Don Quixote and Windmill Courtesy of Wikimedia Commons.

Toshusai_Sharaku__Otani_Oniji_1794Japan to the Rescue – Watchful Waiting 

Left Image : Japanese print on paper Henry L. Phillips Collection 1939 Courtesy of Wikimedia Commons

A thyroid cancer expert, Dr. Yasuhiro Ito of Kobe, Japan, has come up with a similar approach for papillary thyroid cancer, and has a number of studies to back up his statements.

Dr Ito published this in the 2003 Thyroid Journal (24):

“Our preliminary data suggest that papillary microcarcinomas do not frequently become clinically apparent, and that patients can choose observation while their tumors are not progressing, although they are pathologically multifocal and involve lymph nodes in high incidence.”(24)

Dr Ito observed 162 patients with papillary thyroid microcarcinoma (< 10 mm) over 8 years. 70% of tumors either remained stable or decreased in size. Only 10% enlarged by more than 10 mm. Only 1.2% of patients developed neck node metastasis over the 8 years observation. Because of this study, Dr. Ito says the patient can opt for watchful waiting with serial ultrasound follow up studies. Dr Ito says that if follow up ultrasound shows enlarging tumor, or enlarging metastatic neck nodes, then more aggressive surgical treatment is indicated with an excellent prognosis.(24)

In another study of 52 cases, Dr Ito found when the papillary thyroid cancer is found after surgery while examining the histology slides, then no further surgery is needed.(26)

It’s the Pathologist’s Fault – Just Stop Calling It Cancer

623px_Lymph_node_with_papillary_thyroid_carcinomaPerhaps this whole problem is caused by incorrect terminology used by the pathologist who reviews the biopsy slide and uses the word “cancer”, a word that strikes fear and creates undue stress. Once a pathology report with the word “cancer” is placed on the desk, rationality gets thrown out the window, and the patient demands aggressive treatment, usually out of proportion to the actual pathology.

Left Image: Lymph node with metastasis of papillary thyroid carcinoma (middle/bottom of image). The papillary thyroid carcinoma (thyroid cancer) shown here has the classically described appearance (papillary architecture — papillae with fibrovascular cores). The lymph node has several germinal centers (left, top/right of image). Adipose tissue (fat) is seen at the edge of the image (bottom and left). Courtesy of Wikimedia Commons

In the 2003 issue of the International Journal of Surgical Pathology, Dr Rosai presented the Porto Proposal , in which he proposed a change in terminology. Instead of CANCER, he suggested the terminology, papillary microtumor.(22)

Others (Hazard et al.) proposed “nonencapsulated thyroid tumor” because “the surgeon may become unduly alarmed when the pathologist reports the presence of carcinoma.”(22)

Harach et al. proposed the term occult papillary tumor, “in order to avoid unnecessary operations and serious psychologic effects on patients.”(22)

Is Treatment of Papillary Micro-Carcinoma Overly Aggressive?

Over the years, we have seen surgical treatment for breast cancer evolve from the overly aggressive and debilitating radical mastectomy procedure, to the current day simple lumpectomy for many small breast cancers. Perhaps treatment for thyroid cancer is going in this same direction, and is playing “catch-up” with the more limited breast cancer treatments.

Dr Ian Hay’s 2008 study published in Endocrine Abstracts followed 900 patients with papillary thyroid microcarcinoma over 54 years. Dr Ian Hay(17):

“neither total thyroidectomy, nor Postoperative Radioactive Iodine Ablation, improved long term outcome during 40 years, in terms of either tumor recurrence or cause-specific mortality.”(17)

Dr Hay advocates removal of the tumor with unilateral lobectomy, saying that it was unnecessary to perform total thyroidectomy or radioactive iodine treatment, since they did not improve prognosis compared to unilateral thyroid lobectomy alone.(17)

The Role of Iodine Supplementation

You might ask the obvious question, “Thyroid nodules are found in 67% of the population. What is causing this?” I would suggest that the most likely explanation is sub-clinical iodine deficiency in the population. Iodine deficiency causes thyroid enlargement (goiter), thyroid nodules, and thyroid cancer.

Thyroid cancer appears linked to Iodine deficiency in both animal models and humans. Studies have shown that iodine deficiency is associated with increased anaplastic thyroid cancer, the aggressive type unresponsive to treatment and associated with high mortality rate.(15)

Population studies in which iodine supplementation was given showed reduced mortality from thyroid cancer.(11)  Incidentally, this reduced mortality was also associated with an increase in well differentiated papillary cancers, again suggesting the papillary type to be associated with a better outcome. Make sure to take Iodine supplements to reduce the risk of dangerous types of thyroid cancer.

For more information on Iodine as a breast cancer preventive, click here.

JAMA Gets On Board- Thyroid Cancer Epidemic is Due to Over-Diagnosis

Update Feb 2014: Article by Welch and Davies in JAMA Otolaryngology .(1)

Since 1975, the incidence of thyroid cancer has now nearly tripled, from 5 to 15 per 100,000 population mostly from papillary thyroid cancer. The ongoing epidemic of thyroid cancer in the United States is not an epidemic of disease but rather an epidemic of diagnosis. The problem is particularly acute for women,”(1)

Our clinical experience with thyroid nodules.

Over the years, a number of patients, seeking to avoid surgery, have come to our office because of recommendations for thyroidectomy for small thyroid nodules.  In such cases we follow the nodule with serial ultrasound exams along with medical treatments such as natural thyroid, iodine and selenium supplements.  In all of our cases in which we have followed nodules, they have decreased in size over time, rendering surgery unnecessary.  In no cases was there aresort to surgery.

Many endocrinologists will routinely perform a thyroid sonogram in their office to screen for small nodules. Based on the advice of John Cronan MD and Gilbert Welch MD, we intentionally do not do this.  We do not perform thyroid sonograms on new patients, unless they already have a documented nodule.  In which case, we follow the nodules with serial ultrasound.(2)  None have required surgery when treated medically with our protocol.

Addendum 2015:
Durante C, Costante G, Lucisano G, et al. The Natural History of Benign Thyroid Nodules. JAMA. 2015;313(9):926-935.

Conclusions and Relevance: Among patients with asymptomatic, sonographically or cytologically benign thyroid nodules, the majority of nodules exhibited no significant size increase during 5 years of follow-up and thyroid cancer was rare. These findings support consideration of revision of current guideline recommendations for follow-up of asymptomatic thyroid nodules.

Articles with related content:

Hashimoto’s Thyroiditis Articles

Hashimotos Thyroiditis and Selenium Part One

Hashimotos, Selenium and Iodine, Part Two

Thyroid Articles

Ann Nicole Smith and Hypothyroidism

Why Natural Thyroid is Better than Synthetic Part One

Why Natural Thyroid is Better Part Two

The TSH Reference Range Wars – Part One

TSH Wars, Part Two

Thyroid Nodules

The Thyroid Nodule Epidemic

The Strange Case of the Autonomous Thyroid Nodule

Jeffrey Dach MD
7450 Griffin Road
Suite 190
Davie, Florida 33314

Links and References

JAMA Otolaryngol Head Neck Surg. 2014 Feb 20. doi: 10.1001/jamaoto.2014.1. [Epub ahead of print]
Current Thyroid Cancer Trends in the United States.
Davies L1, Welch HG2. IMPORTANCE We have previously reported on a doubling of thyroid cancer incidence-largely due to the detection of small papillary cancers. Because they are commonly found in people who have died of other causes, and because thyroid cancer mortality had been stable, we argued that the increased incidence represented overdiagnosis. OBJECTIVE To determine whether thyroid cancer incidence has stabilized. DESIGN Analysis of secular trends in patients diagnosed with thyroid cancer, 1975 to 2009, using the Surveillance, Epidemiology, and End Results (SEER) program and thyroid cancer mortality from the National Vital Statistics System. SETTING Nine SEER areas (SEER 9): Atlanta, Georgia; Connecticut; Detroit, Michigan; Hawaii; Iowa; New Mexico; San Francisco-Oakland, California; Seattle-Puget Sound, Washington; and Utah. PARTICIPANTS Men and women older than 18 years diagnosed as having a thyroid cancer between 1975 and 2009 who lived in the SEER 9 areas. INTERVENTIONS None. MAIN OUTCOMES AND MEASURES Thyroid cancer incidence, histologic type, tumor size, and patient mortality. RESULTS Since 1975, the incidence of thyroid cancer has now nearly tripled, from 4.9 to 14.3 per 100 000 individuals (absolute increase, 9.4 per 100 000; relative rate [RR], 2.9; 95% CI, 2.7-3.1). Virtually the entire increase was attributable to papillary thyroid cancer: from 3.4 to 12.5 per 100 000 (absolute increase, 9.1 per 100 000; RR, 3.7; 95% CI, 3.4-4.0). The absolute increase in thyroid cancer in women (from 6.5 to 21.4 = 14.9 per 100 000 women) was almost 4 times greater than that of men (from 3.1 to 6.9 = 3.8 per 100 000 men). The mortality rate from thyroid cancer was stable between 1975 and 2009 (approximately 0.5 deaths per 100 000). CONCLUSIONS AND RELEVANCE There is an ongoing epidemic of thyroid cancer in the United States. The epidemiology of the increased incidence, however, suggests that it is not an epidemic of disease but rather an epidemic of diagnosis. The problem is particularly acute for women, who have lower autopsy prevalence of thyroid cancer than men but higher cancer detection rates by a 3:1 ratio.

2)  Editorials – Thyroid Nodules: Is It Time to Turn Off the US Machines? by John J. Cronan, MD June 2008 Radiology, 247, 602-604. A NORMAL FINDING

The prevalence of thyroid nodules in the U.S. population is dependent on the tool used for interrogation of the thyroid. With simple palpation, 4%–7% of the population has a thyroid nodule. At autopsy, 50%–60% of the population is found to have a thyroid nodule. However, the reservoir of clinically silent impalpable nodules is truly expanded when high-resolution US is utilized for thyroid evaluation. Up to 67% of the population evaluated with US will have an incidental thyroid nodule (3). Conservatively, if 50% of the U.S. population (approximately 300 million) has a nodule, we are dealing with a potential reservoir of 150 million Americans with a thyroid nodule. This pool of patients is only awaiting US interrogation in order to classify thyroid nodules requiring diagnostic assessment and categorization as benign or malignant.

Confirming the power of US, there has been a 2.4-fold increase in the reported incidence of thyroid nodules in the past 3 decades that is directly related to the use of US to search for thyroid nodules. Also contributing to this expanding pool of thyroid nodules is the incidental detection of nodules via computed tomography and magnetic resonance imaging (2). This increase in the detection of nodules has been accompanied by a three-fold increase in thyroid aspirates in the decade of 1995–2005 (4). A recent trend in the utilization of in-office US, often by endocrinologists, is accelerating the utilization of US in the general patient population and contributing to the detection of these nonpalpable nodules (5).


Once a thyroid nodule is detected, the binary question remains, is it benign or malignant? Depending on the published series referenced, 6%–13% of thyroid nodules chosen for FNA will yield malignancy (2,6). Surprisingly, size is not a factor in determining the rate of malignancy. In fact, the incidence of thyroid cancer identified in nonpalpable thyroid nodules is the same as that identified in patients with palpable nodules (3).

The majority of thyroid cancers detected incidentally are papillary in origin. Unlike its malevolent associate anaplastic thyroid cancer, which while accounting for only 1%–2% of thyroid cancers is responsible for over half the cancer deaths, papillary thyroid cancer is very benign (7).

The American Cancer Society estimated in 2005 that 25,690 new cancers of the thyroid were reported and 1460 individuals died of thyroid malignancy (8). Since papillary is the dominant thyroid cancer and is well differentiated, the prognosis is remarkably good, with a reported 30-year survival of 95% (8).

With these facts in mind, despite the exponential increase in the detection of both nodules and thyroid malignancy, the incidence of thyroid deaths has been stable during the past 40 years. The entire increase in thyroid malignancy is secondary to papillary cancers and is related to the increased diagnostic scrutiny resulting in an apparent increase in incidence of thyroid cancer that is all papillary (5). This nonpalpable thyroid cancer has little biologic significance (9).

In fact, in an autopsy series, Harach et al (10) opined that occult papillary cancer might well be a “normal” finding. Utilizing 2–3-mm sections of the thyroid in 101 autopsies, they located papillary cancer in 36% of people—all without any signs or symptoms during their life (10).

The Journal of Clinical Endocrinology & Metabolism Volume 87 Issue 5 – May 1, 2002.
Nonpalpable Thyroid NodulesManaging an Epidemic by Douglas S. Ross Massachusetts General Hospital and Harvard Medical School Boston.

Because of the discrepancy between the prevalence of clinically apparent thyroid cancer and occult thyroid cancer, it is believed that most occult thyroid cancers have little biologic significance.

Keith Heller MD – The Unreal Epidemic

Do All Cancers Need to Be Treated? The Role of Thyroglobulin in the Management of Thyroid Cancer – The 2006 Hayes Martin Lecture – Keith S. Heller, MD.  Arch Otolaryngol Head Neck Surg. 2007;133(7):639-643.

We seem to be facing an epidemic of thyroid cancer. After a relatively long period of stability, the incidence of thyroid cancer has virtually doubled in the past 20 years.7 At a time when the incidence of most cancers is either decreasing, relatively stable, or increasing only minimally, thyroid cancer is increasing at a rate far greater than any other cancer in this country; a rate that is now approaching 7% a year.

I do not believe that this epidemic is real. It is due to improved diagnostic scrutiny, ultrasonography, and other imaging studies and the increasing use of ultrasound-guided FNAB. We may be diagnosing and treating cancers that have no clinical significance.

We have embarked on a quixotic quest to rid our patients of microscopic and probably clinically unimportant thyroid cancer. We need to refocus our efforts, not to detect more occult disease, but to identify and cure those few patients whose disease is likely to shorten their lives. We need to improve our accuracy in the evaluation of the indeterminate thyroid nodule. We are performing far too many unnecessary thyroidectomies. We need to have a greater appreciation of the importance of risk stratification in predicting not only those who will do well, but those who will almost certainly do poorly. We need to concentrate less on the detection of subclinical disease and more on the identification of patients with clinically low-risk disease who are at a higher risk of recurrence. We need to learn to identify those patients with small cancers who perhaps do not need any treatment at all. Finally, we need to improve our treatment of patients with advanced and aggressive disease.

I have been privileged, in the 28 years that I have been in practice, to have personally operated on and cared for almost 1000 patients with thyroid cancer, including being the initial operating surgeon on about 800 patients with differentiated thyroid cancer (DTC).

I compared 100 consecutive patients operated on between 1991 and 1995 with the most recent 100 patients with DTC and determined the way in which these thyroid cancers were initially discovered (Table 1).

There has been a profound change in these 15 years. In the earlier group, neck masses were felt by the physician or patient in about 90%, including 9% with palpable nodes. In recent times, patients presenting with palpable nodes have been rare, but 27% of cancers were discovered with imaging studies. These have included carotid duplex scans, magnetic resonance imaging scans of the neck to evaluate neck pain, and more recently positron emission tomographic scans performed to evaluate other malignant lesions. They also include what I consider unindicated thyroid imaging, for example, in patients who have vague complaints that are not an appropriate indication for ultrasonography. We are finding cancers now that would not have been found 15 years ago.

There is no longer a controversy about the extent of surgery to be performed or the need for radioactive iodine (RAI) ablation. Most endocrinologists in this country believe that the appropriate initial treatment for almost all DTC is total or near-total thyroidectomy followed by RAI ablation. I know that there are those of you who disagree strongly with this approach, but I believe this is the standard of care for most patients in the United States today.

Positive Lymph Nodes Not Correlated with Survival

We know that occult lateral cervical lymph node metastases are common. In 1971, Attie et al11 presented their experience with elective neck dissection for DTC. In 115 patients who underwent elective neck dissection, 69% had positive nodes. In their patients with positive nodes there were no recurrences or deaths.

In 1996, Grebe and Hay12 published an excellent review of the literature, including all articles correlating the presence of metastatic disease in the neck with prognosis. Not a single article demonstrated a correlation between positive nodes and ultimate survival in patients with papillary cancer. The vast majority of articles showed no correlation with prognosis in patients with follicular or mixed papillary and follicular carcinoma.

It seems safe to conclude that not only does an elevated stimulated thyroglobulin detect disease but an undetectable stimulated thyroglobulin at the first initial follow-up evaluation is predictive of cure and that RAI scanning provides little additional information.

All of these studies, guidelines, and recommendations lack data that prove that the presence of these minimally involved lymph nodes in any way affects the patient’s prognosis nor are there any data that the removal or treatment of these nodes improves their survival. I find these guidelines very troubling for those reasons.

Thyroid cancer has become relatively common. Death from thyroid cancer remains rare. Of the 30 000 new cases of thyroid cancer expected this year, only 1500 will result in deaths.6

While the incidence of thyroid cancer has increased dramatically, the death rate has been stable. How is this explained? One might assume that our treatments are getting better. I do not really believe that is the case. It is helpful to identify which patients actually die of thyroid cancer. The National Cancer Database includes more than 50 000 patients with thyroid cancer treated between 1985 and 1995.24 In that cohort, 2% of patients had anaplastic thyroid cancer, with a mortality of 85%. Extrapolating that to our current number of thyroid cancers per year we would expect roughly 500 deaths this year from anaplastic cancer. A similar calculation for medullary cancer yields an additional 300 deaths. Patients with DTC who present with stage IV disease were found to have 50% mortality. That would account for another 150 deaths. About 1000 of the 1500 deaths expected this year would be due to these aggressive cancers. In addition, other aggressive histologic subtypes such as tall cell and insular carcinoma need to be considered as well as other high-risk patients.

Even if these calculations overestimate the number of aggressive cancers, the obvious conclusion is that very few patients die of apparently curable, low-risk thyroid cancer. Most patients who ultimately die of thyroid cancer can be identified at the time of their initial treatment and followed up aggressively and appropriately.


Increasing Incidence of Thyroid Cancer in the United States, 1973-2002 by Louise Davies, MD, MS; H. Gilbert Welch, MD, MPH JAMA. 2006;295:2164-2167.

We found that the incidence of thyroid cancer in the United States more than doubled over the past 30 years and that 87% of the increase was due to the diagnosis of small papillary cancers. Mortality remained stable during this period. Given the known prevalence of small, asymptomatic papillary thyroid cancers at autopsy, we believe this suggests that increased diagnostic scrutiny has caused an apparent increase in incidence of cancer rather than a real increase.

For the forgoing findings to be explained by an increase in the true occurrence of disease, several conditions would need to be met. First, there would have to be a substantial increase in the major risk factor for the disease, ie, radiation. However, if anything, radiation exposure is less common today than it was in the past. The last major nuclear atmospheric tests in the United States were conducted in 1961.16 Therapeutic radiation for common benign diseases of the head and neck has not been used since the late 1950s, when it was used for multiple conditions such as acne, adenoid hypertrophy, tinea capitis, and thymus enlargement.16 Second, detection and treatment would have to improve in order to keep mortality stable. These advances would need to match the pace of the underlying increase in disease burden; they could not be too slow or mortality would increase, and they could not be too fast or mortality would decrease.

Some might argue that, while there has been an increase in the true occurrence of disease, there has not been enough time for increased mortality to appear. However, for this to be an explanation for the trend here, the lead time would have to be extraordinarily long—greater than the 30 years in which mortality has been stable.

Another possible explanation is that increasing incidence in the face of stable mortality represents a new category of thyroid cancer—symptomatic but not lethal. That is, there might be a growing number of people with thyroid cancer who are symptomatic but who will not die from their disease. The SEER data provide some evidence that this could explain, at best, only a small portion of the increase. One marker of increased symptoms from papillary cancer relates to the incidence of metastatic disease; however, this changed little over our analysis period (the incidence of metastatic papillary cancer increased by 0.15 per 100 000, while the overall incidence of papillary cancer increased by 5 per 100 000). Local symptoms from papillary cancer largely relate to size, resulting in dysphagia and orthopnea, and would generally be seen in cancers larger than 5 cm. The incidence of these large cancers also changed little (<3% of the increased incidence from 1988 to 2002 involved cancers of this size). Small cancers can become locally invasive and cause dysphagia or orthopnea, but this type of progression typically occurs when they are of the poorly differentiated type, and these categories of cancer (anaplastic and medullary) have also remained stable.

Alternatively, these changes could be explained by a change in the pathological criteria for thyroid cancer. The World Health Organization histological criteria for diagnosis of papillary thyroid cancer remained the same between 1988 and 2002, a period during which incidence of this category nearly doubled.17 While one might argue that the criteria could nevertheless have changed in practice, the finding that one third of adults harbor subclinical papillary cancer was based on pathological criteria from the early 1980s—making it difficult to believe that the pathological threshold for papillary cancer has decreased substantially since then.

Thus, we believe increased diagnostic scrutiny is the most likely explanation for the apparent increase in incidence. Advances in imaging and diagnostic techniques have made it more likely that cancers from this subclinical reservoir are detected. Because many of these cancers would likely never have caused symptoms during life, epidemiologists have labeled the phenomenon “overdiagnosis”—a term perhaps most familiar in the setting of prostate cancer.18

The case for overdiagnosis is strengthened because almost all the increased incidence is attributable to the detection of small cancers best discovered by use of the new technologies—ultrasound and fine-needle aspiration. In the 1980s, ultrasound came into widespread use.19 While thyroid ultrasound cannot diagnose a thyroid nodule as malignant, it can detect nodules as small as 0.2 cm. Thus, ultrasound is much more sensitive than physical examination alone, which only detects nodules that are nearly an order of magnitude larger, and physical examination has relatively low sensitivity (detects only about 40% of nodules >1.5 cm).20 The second technology is fine-needle aspiration, which became widely adopted in the 1990s. Fine-needle aspiration allows for cytological assessment of a thyroid mass and can be performed quickly during an office visit.21 It has largely replaced nuclear medicine scans, much more involved tests that required dietary restrictions prior to the test, took several hours to complete, and frequently produced indeterminate results. The combination of the ability to detect small nodules and then aspirate their contents has clearly facilitated the diagnosis of these smaller cancers.

Overdiagnosis is a cause for concern because it makes it hard to identify which patients need treatment. In our data, most patients diagnosed with thyroid cancer underwent total thyroidectomy. This was the case even if the cancer was papillary and very small—75% of those with papillary cancers found to measure less than 1 cm underwent the procedure. Total thyroidectomy carries small but significant risks of operative complications, including permanent hypoparathyroidism and damage to the recurrent laryngeal nerve, which can result in chronic aspiration and compromised voice quality. Additionally, thyroidectomy commits the patient to a lifetime of thyroid replacement therapy and, as of recently, a recommendation of long-term surveillance for recurrent disease.

Furthermore, there are reasons to worry that the problem of identifying which patients need treatment will only get worse. Masses in the thyroid gland, which might prompt testing for thyroid cancer, are very common. Twenty percent of US adults have a palpable lesion of the thyroid gland, and 67% have a mass that can be visualized on ultrasound.22 While thyroid ultrasound has traditionally been performed in the radiology department, it is increasingly performed in the physician’s office. If ultrasound continues to grow as an office-based adjunct to physical examination, there could be a dramatic increase in the number of nodules—and, ultimately cancers—identified.

We found an increase in the apparent incidence of thyroid cancer without any clinical impact on mortality. Further studies will be needed to determine if a more cautious diagnostic approach—perhaps simply providing follow-up for symptomatic thyroid nodules—is worthwhile. In addition, papillary cancers smaller than 1 cm could be classified as a normal finding.

6) Thyroid Nodules by MARY JO WELKER, M.D., and DIANE ORLOV, M.S., C.N.P.
AAFP Magazine

Palpable thyroid nodules occur in 4 to 7 percent of the population, but nodules found incidentally on ultrasonography suggest a prevalence of 19 to 67 percent. The majority of thyroid nodules are asymptomatic. Because about 5 percent of all palpable nodules are found to be malignant, the main objective of evaluating thyroid nodules is to exclude malignancy. Laboratory evaluation, including a thyroid-stimulating hormone test, can help differentiate a thyrotoxic nodule from an euthyroid nodule. In euthyroid patients with a nodule, fine-needle aspiration should be performed, and radionuclide scanning should be reserved for patients with indeterminate cytology or thyrotoxicosis. Insufficient specimens from fine-needle aspiration decrease when ultrasound guidance is used. Surgery is the primary treatment for malignant lesions, and the extent of surgery depends on the extent and type of disease. Ablation by postoperative radioactive iodine is done for high-risk patients–identified as those with metastatic or residual disease. While suppressive therapy with thyroxine is frequently used postoperatively for malignant lesions, its use for management of benign solitary thyroid nodules remains controversial. (Am Fam Physician 2003;67:559-66,573-4. Copyright© 2003 American Academy of Family Physicians.)


Once a thyroid nodule is detected, the binary question remains, is it benign or malignant? Depending on the published series referenced, 6%–13% of thyroid nodules chosen for FNA will yield malignancy (2,6). Surprisingly, size is not a factor in determining the rate of malignancy. In fact, the incidence of thyroid cancer identified in nonpalpable thyroid nodules is the same as that identified in patients with palpable nodules (3).

The majority of thyroid cancers detected incidentally are papillary in origin. Unlike its malevolent associate anaplastic thyroid cancer, which while accounting for only 1%–2% of thyroid cancers is responsible for over half the cancer deaths, papillary thyroid cancer is very benign (7). The American Cancer Society estimated in 2005 that 25 690 new cancers of the thyroid were reported and 1460 individuals died of thyroid malignancy (8). Since papillary is the dominant thyroid cancer and is well differentiated, the prognosis is remarkably good, with a reported 30-year survival of 95% (8). With these facts in mind, despite the exponential increase in the detection of both nodules and thyroid malignancy, the incidence of thyroid deaths has been stable during the past 40 years. The entire increase in thyroid malignancy is secondary to papillary cancers and is related to the increased diagnostic scrutiny resulting in an apparent increase in incidence of thyroid cancer that is all papillary (5). This nonpalpable thyroid cancer has little biologic significance (9). In fact, in an autopsy series, Harach et al (10) opined that occult papillary cancer might well be a “normal” finding. Utilizing 2–3-mm sections of the thyroid in 101 autopsies, they located papillary cancer in 36% of people—all without any signs or symptoms during their life (10).

As Ross (4) pointed out to his endocrinology colleagues, we have an epidemic of thyroid nodules secondary to technology. There is no proof that our intervention on these nonpalpable nodules has any effect on improving the health and welfare of the population.

CMAJ • November 20, 2007; 177 (11).  Explaining the increasing incidence of differentiated thyroid cancer by Jacques How, MB ChB and Roger Tabah, MD Jacques How is with the Division of Endocrinology and Roger Tabah is with the Department of Surgery, Montreal General Hospital, McGill University Health Centre, Montréal, Que.

Managing Small Thyroid Cancers by Ernest L. Mazzaferri, MD JAMA. 2006;295:2179-2182.

Davies and Welch attribute the increasing incidence of PTC to overdiagnosis or “increased diagnostic scrutiny,” which makes it difficult to identify which patients need treatment, but they also caution that this problem is only likely to get worse, suggesting that small asymptomatic thyroid nodules should be followed up for a period of time without immediately initiating diagnostic investigation.

Cancer. 1985 Aug 1;56(3):531-8. Occult papillary carcinoma of the thyroid. A “normal” finding in Finland. A systematic autopsy study. by Harach HR, Franssila KO, Wasenius VM.

The thyroids from 101 consecutive autopsies from Finland were subserially sectioned at 2- to 3-mm intervals. From 36 thyroids, 52 foci of occult papillary carcinoma (OPC) were found, giving a prevalence rate of 35.6%, the highest reported rate in the world. The rate was higher, although not significantly, in males (43.3%) than in females (27.1%), but it did not correlate to the age of the patients. Twenty-six glands contained one tumor focus and ten glands contained two to five tumor foci. Only a minority of the smallest tumors can be detected with the method used. The probable number of OPCs over 0.15 mm in diameter was calculated to be about 300 in this material. The tumor diameter varied from 0.15 mm to 14.0 mm, with 67% of tumors under 1.0 mm. The smallest tumors were usually circumscribed and were composed almost solely of follicles. Larger tumors had more papillary structures and were often invasive. Fibrosis and, in the largest OPCs, lymphocytic reaction were seen around the invasive islands. All tumors were positively stained for thyroglobulin and all but one of the tumors stained positively for epidermal keratin. OPC appears to arise from follicular cells of normal follicles. Apparently the great majority of the tumors remain small and circumscribed and even from those few tumors that grow larger and become invasive OPCs only a minimal proportion will ever become a clinical carcinoma.

According to the study, OPC can be regarded as a normal finding which should not be treated when incidentally found. In order to avoid unnecessary operations it is suggested that incidentally found small OPCs (less than 5 mm in diameter) were called occult papillary tumor instead of carcinoma.


Cancer – Iodine deficiency, radiation dose, and the risk of thyroid cancer among children and adolescents in the Bryansk region of Russia following the Chernobyl power station accident by V Shakhtarin1, AF Tsyb1, VF Stepanenko1, MY Orlov2, KJ Kopecky3 and S Davis3

Influence of iodine deficiency and iodine prophylaxis on thyroid cancer histotypes and incidence in endemic goiter area. Huszno B, Szybinski Z, Przybylik-Mazurek E, Stachura J, Trofimiuk M, Buziak-Bereza M, Golkowski F, Pantoflinski J.

The aim of the study was to evaluate the correlation between thyroid cancer histotype and incidence rate (IR) and iodine nutrition level in two endemic goiter areas: the districts of Krakow and Nowy Sacz. The suspension of iodine prophylaxis in Poland in 1980 resulted in increased goiter prevalence in schoolchildren and adults and elevated TSH levels in newborns in the early 1990s. Since 1992 a rise in thyroid cancer IR was observed. Thyroid cancer IR in the Krakow population was 2.22 in 1986; 3.62 in 1995 and 6.02 in 2001; in Nowy Sacz: 1.52; 2.59 and 3.88 respectively. In 1986 papillary/follicular cancer ratio in both areas was about 1.0–the value typical of iodine deficient areas. After restoring the obligatory iodine prophylaxis in 1997, a significant decrease in elevated TSH concentration in newborns and urinary iodine concentration increase in schoolchildren were observed. A relative rise in the incidence of papillary thyroid cancer and decrease in follicular cancer, resulting in rise in papillary/follicular thyroid cancer ratio up to 5.9 in 2001 was also observed.
Since 1999 no further thyroid cancer IR increase was noted.

In conclusion, a significant increase in differentiated thyroid cancer IR was observed in association with the iodine prophylaxis suspension. Changes in thyroid cancer histotypes in 1986-2001 and a significant decrease in incremental rate of differentiated thyroid cancer probably reflect the influence of effective iodine prophylaxis. The significant difference between IR of thyroid cancer incidence in the districts of Krakow and Nowy Sacz may be related to differences in the exposure to radiation after the Chernobyl accident.

Thyroid. 1997 Oct;7(5):733-41. Incidence and clinical characteristics of thyroid carcinoma after iodine prophylaxis in an endemic goiter country. Bacher-Stier C, Riccabona G, Tötsch M, Kemmler G, Oberaigner W, Moncayo R. Department of Nuclear Medicine, University of Innsbruck, Austria.

Iodized salt prophylaxis has been performed in Austria since 1963. Through this approach, mean urinary iodine excretion has been normalized to 144+/-23.5 microg/g creatinine per day. Thus Tyrol is no longer an endemic goiter area. We have analyzed the impact of iodized salt prophylaxis on thyroid cancer (TC) comparing data from the early 1960s with those corresponding to the period 1986 to 1995, when iodine supply was normalized. The study included 439 patients from Tyrol and Southern Tyrol. The incidence of TC in Tyrol has risen during the past decades from 3.07 between in 1957 and 1970 to 7.8 between 1990 and 1994 (CR/100000/year). We observed a rise in the percentage of differentiated adenocarcinomas (56% to 91.5%) with a predominance of papillary TC (54.4%) along with a decrease of anaplastic TC. In addition to these histological features, a shift to less advanced TNM stages, eg, T1-3, N0-1a, M0, was obvious, increasing from 29% to 72.2%, whereas advanced tumors, ie, T4 or N1b or M1, decreased from 71% to 28%.

These changes have significantly improved prognosis. The current 5-year survival rate is 90.7% as compared with a rate of 73% in the 1960s; the values for 7-year survival are 89% and 48%, respectively. The marked effects of age, tumor stages, and histology on prognosis were confirmed with the Kaplan-Meier method. We conclude that together with normalization of iodine supply in an endemic goiter region the epidemiological profile of TC has changed. Even though the incidence of TC has risen, prognosis has significantly improved due to a shift towards differentiated forms of TC that are diagnosed at earlier stages.


Iodine: deficiency and therapeutic considerations – Alternative Medicine Review, June, 2008 by Lyn Patrick

Iodine deficiency is also associated with increased risk for thyroid carcinoma in animal models and humans. (5-8)

(5.) Schaller RT Jr, Stevenson JK. Development of carcinoma of the thyroid in iodine-deficient mice. Cancer 1966;19:1063-1080.
(6.) Mellemgaard A, From G, Jorgensen T, et al. Cancer risk in individuals with benign thyroid disorders. Thyroid 1998;8:751-754.
(7.) Burgess JR, Dwyer T, McArdle K, et al. The changing incidence and spectrum of thyroid carcinoma in Tasmania (1978-1998) during a transition from iodine sufficiency to iodine deficiency. J Clin Endocrinol Metab 2000;85:1513-1517.
(8.) Franceschi S, Preston-Martin S, Dal Maso L, et al. A pooled analysis of case-control studies of thyroid cancer. IV. Benign thyroid diseases. Cancer Causes Control 1999;10:583-595.


The frequency of cold thyroid nodules and thyroid malignancies in patients from an iodine-deficient area

Antonino Belfiore, MD 1, Giacomo L. La Rosa, MD 1, Giuseppina Padova, MD 1, Lidia Sava, MD 1, Orazio Ippolito, MD 2, Riccardo Vigneri, MD 1 * Cattedra di Endocrinologia e Patologia Costituzionale dell’Università di Catania, Ospedale Garibaldi, Catania, Italy

An analysis of thyroid cancer morbidity was carried out in two adjacent areas of Sicily differing in iodine intake. A consecutive series of 911 patients with cold nodules from an iodine-deficient area (IDA) and 2537 from a control area (CA) were examined by fine needle aspiration and selected for surgery and pathologic examination. Malignancies were found in 27 of the patients (2.96%) from the IDA and in 139 patients (5.48%) from the CA. Based on a population survey indicating that cold thyroid nodules were 2.5 times more frequent in the IDA with respect to the CA, we calculated a prevalence of 127 thyroid cancers per 105 inhabitants in the IDA versus 93 in the CA (P < 0.001). Moreover, follicular and anaplastic carcinomas were three times more frequent in the IDA than in the CA (75 versus 24 cases per 105 inhabitants, respectively). These studies indicate that iodine deficiency may be one factor in the development of certain thyroid malignancies in man.

Arq Bras Endocrinol Metab vol.51 no.5 São Paulo July 2007

Relevance of iodine intake as a reputed predisposing factor for thyroid cancer
There is no doubt that introduction of universal iodine prophylaxis in population previously in chronic iodine-deficiency leads to a changing pattern of more prevalent papillary thyroid cancer and declining of follicular thyroid cancer. Also anaplastic thyroid cancer is practically not seen after years of iodine supplementation.

Nippon Rinsho. 2007 Nov;65(11):1953-8. [Epidemiology of thyroid tumors: effect of environmental iodine intake] Kasagi K. Department of Internal Medicine, Takamatsu Red Cross Hospital.

The incidence of thyroid cancer has been reported to be 0.5-1.3%, when assessed by sonographic examination and 3.7-28.4% by histologic examination at autopsies. These incidences are much higher than those of clinically evident thyroid cancer, which are 2.0/100,000 for males and 7.2/100,000 for females, reported in Japan. In iodine deficient areas, chronic stimulation by TSH causes multinodular autonomous growth and function, leading to hyperthyroidism in middle-aged and elderly subjects. Incidence of Plummer’s disease among Japanese with sufficient iodine intake is very low, accounting for 0.5-0.8% of all thyroid nodules and 0.3% of all thyrotoxic patients. The Plummer/Graves ratio was higher than 1 in endemic goiter area before iodine supplementation.

Iodine intake affects the type of thyroid carcinoma. Decreased intake of iodine is associated with higher frequency of follicular and anaplastic cancers and lower frequency of papillary cancer. The high prevalence of papillary cancer(>85%) with good prognosis may explain the preferred selection of partial rather than total thyroidectomy in Japan.


16)  Laryngoscope. 2009 Aug 4. [Epub ahead of print] Survival impact of treatment options for papillary microcarcinoma of the thyroid.
Lin HW, Bhattacharyya N. Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, U.S.A.

OBJECTIVES/HYPOTHESIS:: Evaluate the impact of medical and surgical interventions on the survival of patients with papillary microcarcinoma (PMC) of the thyroid, a common tumor with an increasing worldwide incidence. STUDY DESIGN:: Cross-sectional population analysis of a prospectively maintained database. METHODS:: Cases of nonmetastatic PMC treated with cancer-directed surgery with or without postoperative radioactive iodine (RAI) therapy were extracted from the Surveillance, Epidemiology and End Results Database (1988-2005). Kaplan-Meier disease-specific survival (DSS) and overall survivals were compared according to extent of thyroidectomy and use of RAI therapy. Cox regression analysis was performed to determine the influence of these factors on survival.

RESULTS:: A total of 7,818 cases of PMC were identified. Overall actuarial survival rates at 10 and 15 years were 96.6% and 96.3%, respectively. DSS was 99.9% at both time intervals, with a total of 10 thyroid cancer-related deaths. There were no significant differences in DSS for patients who underwent total thyroidectomy, near-total/subtotal thyroidectomy, or lobectomy (P = .239). DSS for patients receiving RAI therapy was not significantly different than that of patients who did not (P = .504). On multivariate analysis, only increasing age at diagnosis, successfully predicted poor DSS (P = .001), whereas gender (P = .481), use of RAI therapy (P = .633), and extent of thyroidectomy (P = .104) did not.

CONCLUSIONS:: PMC carries an excellent prognosis with respect to both overall and disease-specific survival that is independent of surgical extent and the use of RAI therapy. An isolated, fine-needle-aspiration proven unilateral PMC focus in a patient lacking evidence of metastatic disease may be treated with lobectomy alone. Laryngoscope, 2009.

17)  Endocrine Abstracts (2008) 16 P685 European Congress of Endocrinology 2008 Berlin, Germany.  Ian Hay, Maeve Hutchinson, Megan Reinalda, Clive Grant, Bryan McIver & Geoffrey Thompson Mayo Clinic, Rochester, Minnesota, USA.

The study aims were to characterize patients with papillary thyroid microcarcinoma (PTM) and to provide data on long-term outcome. About 900 patients with PTM (tumor size 1 cm or less) had treatment at our centre during 1945–2004. Follow-up extended to 54 years. Mean follow-up for 638 survivors was 13.5 years. Recurrence and mortality details were derived from a computerized database. Median tumour size was 7 mm. About 99% of tumors were grade 1; 98% were not locally invasive. About 30% of patients had nodal metastases at presentation. Three (0.3%) had distant spread at diagnosis. About 85% underwent bilateral lobar resection; regional nodes were removed by either ‘node picking’ (27%) or an appropriate compartmental dissection (33%). Tumor resection was incomplete in five cases (0.6%). Radioiodine remnant ablation (RRA) was performed in 155 patients (17%). All-causes survival did not differ from expected (P=0.08); three patients (0.3%), to date, have died of PTM. None of 892 patients with initial complete tumor resection had distant spread during 20 postoperative years. No localized tumor in a female patient was fatal, and no male patient died of PTM in the first 30 postoperative years. Twenty-year and 40-year tumour recurrence rates were 6% and 9%. About 81% of postoperative recurrences have been in regional neck nodes. Higher recurrence rates were seen with multicentric tumors (P=0.002) and node-positive patients (P<0.001), but not after unilateral lobectomy (P=0.49). Tumor recurrence rates did not appear to be significantly improved by RRA (P=0.093).

These results reaffirm that papillary microcarcinoma has an excellent prognosis, if primary tumor is completely resected. More than 99% of PTM patients are not threatened by the risks of distant spread or cancer mortality.

Neither the performance of a total thyroidectomy, nor the administration of postoperative RRA, improved outcome during 40 years, in terms of either tumor recurrence or cause-specific mortality.

Neither total thyroidectomy nor radioiodine remnant ablation improved long-term outcome in 900 patients with papillary thyroid microcarcinoma treated during 1945 through 2004

18)June 11, 2009 ONCOLOGY. Vol. 23 No. 7 Areas of Confusion in Oncology.  What Is the Optimal Initial Treatment of Low-Risk Papillary Thyroid Cancer (and Why Is It Controversial)? Ernest L. Mazzaferri, MD, MACP.  Professor Emeritus The Ohio State University and Courtesy Professor of Medicine. Shands Hospital, University of Florida Gainesville, Florida

The Epidemiologic Controversy

The initial management of thyroid cancer has attracted considerable attention in recent years, mainly because of its relentlessly rising incidence, which increased 2.4-fold from 1973 to 2000.[1] This is almost entirely attributable to a nearly threefold increase in papillary thyroid cancer, which is by far the most common form of the disease, comprising over 80% of all thyroid cancers (throughout this review, percentages are rounded to the nearest integer).[2]

Between 1988 and 2002, when thyroid cancer tumor size was first included in the National Cancer Institute’s Surviellance, Epidemiology and End Results (SEER) database,[1] it became apparent that nearly half the thyroid cancers diagnosed during this period were papillary microcarcinomas 1 cm or smaller, and nearly 90% were papillary cancers 2 cm or smaller.[3] Tumors of this size are widely acknowledged to be associated with low mortality rates, and the overall mortality rates for thyroid cancer during this period remained stable at 0.5 deaths per 100,000 persons in the population.[3]


Papillary thyroid carcinoma accounts for about 80% of all thyroid carcinomas in the United States. The incidence of thyroid cancer increased from 3.6 per 100,000 in 1973 to 8.7 per 100,000 in 2002—a 2.4-fold increase. Virtually the entire increase is attributable to an increase in the incidence of papillary thyroid cancer, which increased from 2.7 to 7.7 per 100,000—a 2.9-fold increase. Between 1988 (the first year SEER collected data on tumor size) and 2002, 49% of the increase consisted of cancers measuring 1 cm or smaller. These trends, combined with the known existence of a substantial reservoir of subclinical cancer and stable overall mortality, suggest that increasing incidence reflects increased detection of subclinical disease, not an increase in the true occurrence of thyroid cancer.


RADIOIODINE PROBABLY OVERTREATMENT FOR MOST THYROID CANCER PATIENTS August 12, 2009 — Surgery is a standard treatment for thyroid cancer. The recommended operation for differentiated thyroid cancer is a total thyroidectomy, and the standard follow-up treatment is radioiodine remnant ablation therapy (RRA), which acts as a “radioactive eraser,” destroying any thyroid tissue that has been left. This is routine clinical practice in the United States, but should it be?

A prominent expert in the field argues that for the majority of patients who receive it, RRA represents overtreatment, with no documented benefit and a possibility for harm. Ian D. Hay, MD, PhD, professor of medicine at the Mayo Clinic in Rochester, Minnesota, mounted a detailed and passionate argument against the use of RRA in a keynote lecture here at the World Congress on Thyroid Cancer 2009.

The majority of patients (>80%) with thyroid cancer have papillary thyroid cancer (PTC), and the majority of PTC patients (about 80% to 85%) are considered low risk. “This is the most common thyroid cancer, and the best one to have,” Dr. Hay said, adding that these patients, after surgery, have a less than 1% chance of dying from their disease.

There is no evidence that RRA is beneficial in this group, Dr. Hay told meeting attendees.

There are no clinical trials or prospective data, he noted. But large reviews of retrospective data have shown that RRA in low-risk PTC patients does not reduce the risk for relapse and does not affect recurrence rates, either at local or distant sites, which is the raison d’etre for using this treatment, he explained. So there is no benefit, but there is a potential for harm, including an increase in the risk for a second primary nonthyroid cancer.

Dr Steve Colley, Consultant Radiologist university Hospital Birmingham NHS Trust, Julie Olliff, Amar Shimal, Alison Page

Data from the US show that there has been an exponential increase in both detection of thyroid nodules, and also of thyroid malignancy. The majority of these cases are papillary carcinoma. It should be noted that despite these increases, the rate of cancer deaths secondary to thyroid cancer have largely remained stable. Papillary thyroid cancer, the commonest type is after all, a relatively benign tumour with excellent prognosis (30 year survival rate 95% (3)).


Renaming Papillary Microcarcinoma of the Thyroid Gland: The Porto Proposal.  Rosai et al. Int J Surg Pathol.2003; 11: 249-251

The 12th Annual Cancer Meeting held at the Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal, on March 3-5, 2003, One of the items was the thyroid neoplasm that is currently designated as papillary microcarcinoma. Pollowing a general discussion on the subject and the conclusion that a change in terminology ought to be considered

However, we are conscious of the fact that the use of the term carcinoma in a pathology report sends to both surgeon and patient a message with a considerable therapeutic, prognostic, psychologic, and financial impact, and we are also aware that these implications are not necessarily tempered by whatever qualifiers and comments one may choose to include in the report. As a result, whenever the diagnosis of PMiC is made, the definite possibility exists that the repercussions of this diagnosis will be far greater that those justified by the biologic potential of the neoplasm. The proposal was therefore discussed at the Porto meeting to rename this entity in a way that would avoid these potential untoward effects while still accurately reflecting its nature. After considering and discarding several alternatives, the term papillary microtumor (PMiT) was chosen, since it was felt that it was the one coming closer to the fulfillment of these requirements. To wit, it indicates the fact that the lesion is of small size, that it is a neoplastic process (remaining purposefully noncommittal about its malignant potential, because while the tumor may show microscopic local invasion, it is clinically benign), and that it belongs to the papillary family of neoplasms.

We would be remiss if we failed to mention that 2 very similar proposals have been made in the past using the same reasoning and aiming at the same goals. Hazard et al. [3] proposed to designate this lesion as nonencapsulated thyroid tumor because “the surgeon may become unduly alarmed when the pathologist reports the presence of carcinoma.” They added that “this may lead to reoperation, radical dissection of the neck or extensive irradiation, all of which are unnecessary and undesirable.” Harach et al. [5] proposed the term occult papillary tumor “in order to avoid unnecessary operations and serious psychologic effects on patients.”


Thyroid Incidentalomas: Management Approaches to Nonpalpable Nodules Discovered Incidentally on Thyroid Imaging Gerry H. Tan, MD, and Hossein Gharib, MD 1 February 1997 | Volume 126 Issue 3 | Pages 226-231

In conclusion, in most patients with nonpalpable thyroid lesions, the risk for clinically malignant disease is low. Moreover, occult papillary tumors that are smaller than 1.5 cm in diameter grow slowly, and patients with such tumors have an excellent prognosis.

It does not seem necessary, practical, or cost-effective to do a biopsy on or to surgically excise all nonpalpable nodules. Our treatment strategy is to observe incidentalomas that are smaller than 1.5 cm in diameter in patients who have a low risk for thyroid cancer (Figure 1).

On the other hand, because nonpalpable papillary thyroid cancer is sometimes associated with local or even distant metastases, the incidentaloma cannot be dismissed as unimportant and careful follow-up is necessary.

In patients who have nodules larger than 1.5 cm in diameter, a history of head or neck irradiation (particularly in childhood), a strong family history of thyroid cancer, or ultrasonographic findings that suggest malignancy, the next appropriate step is ultrasonographically guided biopsy.

Treatment should then be determined on the basis of the cytologic diagnosis. We do not advocate thyroxine suppressive therapy for either a cytologically proven benign nodule that is larger than 1.5 cm in diameter or a benign-appearing nodule that is smaller than 1.5 cm in diameter detected ultrasonographically [45]. Therefore, most nonpalpable nodules do not require immediate treatment and should be followed up simply with palpation. Biopsy should be done if and when the nodules become palpable.

Watchful Waiting Dr Ito Japan


Thyroid. 2003 Apr;13(4):381-7. An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid.  Ito Y, Uruno T, Nakano K, Takamura Y, Miya A, Kobayashi K, Yokozawa T, Matsuzuka F, Kuma S, Kuma K, Miyauchi A.

The recent prevalence of ultrasound-guided fine-needle aspiration biopsy has resulted in a marked increase in the number of patients with papillary microcarcinoma (maximum diameter, </= 10 mm) of the thyroid detected by this sophisticated tool. On the other hand, it is debatable whether patients with papillary microcarcinoma should always undergo surgery after diagnosis, because a high incidence of occult papillary carcinoma has been observed in autopsy studies.

Thus, we proposed observation without surgical therapy as a treatment option in 732 patients diagnosed with papillary microcarcinoma by the above technique from 1993 to 2001. One hundred sixty-two patients chose observation and were classified as the observation group.

During the follow-up period for patients in the observation group, more than 70% of tumors either did not change or decreased in size compared to their initial size at diagnosis. They enlarged by more than 10 mm in 10.2%, and lymph node metastasis in the lateral compartments appeared in only 1.2% of patients during follow-up. On the other hand, 570 patients chose surgical treatment at diagnosis and 56 patients in the observation group who underwent surgery after a period of follow-up were classified as the surgical treatment group. Of these 626 patients, lymph node dissection was performed in 594 patients, and metastasis was confirmed histologically in 50.5%. Multiple tumor formation was seen in 42.8% of patients. In this group, the rate of recurrence was 2.7% at 5 years and 5.0% at 8 years after surgery.

Our preliminary data suggest that papillary microcarcinomas do not frequently become clinically apparent, and that patients can choose observation while their tumors are not progressing, although they are pathologically multifocal and involve lymph nodes in high incidence.

World J Surg. 2004 Nov;28(11):1115-21.  Papillary microcarcinoma of the thyroid: how should it be treated?
Ito Y, Tomoda C, Uruno T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Kuma K, Miyauchi A. Department of Surgery, Kuma Hospital, Chuo-ku, 650-0011 Kobe City, Japan.

We previously demonstrated that (1) most papillary microcarcinomas can be followed without surgical treatment and (2) when surgery is performed, patients with lateral lymph node metastasis detected on preoperative ultrasonography (US) are more likely to develop recurrence. In this study, we further investigated the application of these strategies.

To date, we have observed 211 patients (average follow-up 47.9 months). In more than 70% of these patients the tumor size did not increase during the follow-up period. There were no clinicopathologic features linked to tumor enlargement except in tumors > or = 7 mm, which tended to enlarge in patients followed for 4 years.

To evaluate not only whether observation can continue but also how to dissect the lymph nodes optimally at surgery, US diagnosis for lateral node metastasis is essential because the presence of US-diagnosed lateral metastasis is an even stronger predictive marker for recurrence than the presence of pathologically confirmed node metastasis.

The positive predictive value (PPV) was 80.6% for US but reached 100% if fine-needle aspiration biopsy (FNA of nodes or FNAB-thyroglobulin measurement is added.

Furthermore, carcinomas occupying the upper region of the thyroid more frequently showed US-diagnosed and pathologically confirmed lateral metastasis, and those measuring > or = 7 mm were more likely to show pathologically confirmed lateral metastasis.

These findings suggest that, for papillary microcarcinoma: (1) US-diagnosed lateral metastasis is a strong marker predicting a worse relapse-free survival; (2) FNAB of nodes and FNAB-thyroglobulin measurement are useful tools for evaluating lymph node metastasis; and (3) careful US evaluation for lateral metastasis is necessary in patients with a tumor measuring > or = 7 mm or that is located in the upper region of the thyroid both during observation and preoperatively.

26) Anticancer Res. 2007 Mar-Apr;27(2):1039-43. Long-term follow-up for patients with papillary thyroid carcinoma treated as benign nodules. Ito Y, Higashiyama T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Kuma K, Miyauchi A.

BACKGROUND: The recent prevalence of ultrasonography and fine-needle aspiration biopsy (FNA has facilitated the detection and diagnosis of papillary thyroid carcinoma. However, there are still cases that are preoperatively misdiagnosed and treated as benign nodules because ultrasonographic and FNAB findings do not provide sufficient evidence for a malignant diagnosis. In this study, we investigated the clinical outcomes of patients with papillary carcinoma that had not been recognized preoperatively.

PATIENTS AND METHODS: We investigated the prognoses of 56 patients with papillary carcinoma who underwent thyroidectomy without node dissection under a diagnosis of benign nodules.

RESULTS: None of the patients underwent further surgery such as completion total thyroidectomy and node dissection after the pathological diagnosis of papillary carcinoma was established. However, to date, only 3 patients (5.3%) showed recurrence 116, 133 and 148 months after the initial surgery, respectively. Two patients showed recurrence in the remnant thyroid and one showed recurrence in the bone. None of the patients have died of thyroid carcinoma.

CONCLUSION: Papillary carcinomas misdiagnosed as benign nodules on ultrasonography and FNAB are indolent and very slow-growing. Immediate further surgery is not needed for such cases, even if they were resected as benign nodules at the initial surgery.

27) J Clin Pathol. 2004 October; 57(10): 1041–1046.  Papillary carcinoma of the thyroid in Japan: subclassification of common type and identification of low risk group – K Kakudo,1 W Tang,1 Y Ito,2 I Mori,1 Y Nakamura,1 and A Miyauchi2 1Department of Pathology, Wakayama Medical University, Wakayama, 641-8509, Japan 2Kuma Hospital, Kobe Japan


ORIGINAL ARTICLE 2007 | Volume : 53 | Issue : 1 | Page : 23-26. Post Graduate Medicine.  Microscopic papillary thyroid cancer as an incidental finding in patients treated surgically for presumably benign thyroid disease.  GH Sakorafas1, V Stafyla1, T Kolettis1, G Tolumis2, G Kassaras1, G Peros1 1 Department of Surgery, 251 Hellenic Air Force Hospital, Athens, Greece

In autopsy studies, the incidence of PTMC ranges from 3-36%.[2],[3] Because of this high incidence, Harach et al . from Finland concluded that “…occult papillary thyroid carcinoma are so common in Finland … that they can be regarded as a normal finding”.[3] Similarly, in surgical studies, incidental foci of PTMC were found in a large percentage of patients after thyroidectomy for a presumably benign thyroid disease, ranging from 2-24%.[4],[5]

In our study, PTMC was diagnosed in 7.1% (27 of 380) of patients who were treated surgically for presumably benign thyroid disease. Multifocality is common in PTMC and is observed in 20-46% of cases (~ 41% in this study).[2],[5],[6]

Interestingly, lymph node metastases (usually micrometastases) can be detected in a significant percentage of patients with PTMC (up to 40%) and, in a small percentage of patients, these metastases may precede the clinical evidence of the primary tumor.[7]

The high incidence of PTMC in autopsy studies suggests that most of them have a relatively “benign” biological behavior. These studies showed that a significant percentage of patients (up to 36%) who died of diseases other than thyroid cancer had PTMC that remained asymptomatic throughout their lives.[3],[8] The discordance between the prevalence of PTMC and population estimates of death from cancer further support that PTMC is an indolent disease.[9],[10]

Molecular Markers

29)  Comparative genomic hybridization, BRAF, RAS, RET, and oligo-array analysis in aneuploid papillary thyroid carcinomas. Rodrigues R, Roque L, Espadinha C, Pinto A, Domingues R, Dinis J, Catarino A, Pereira T, Leite V. Cytogenetic Laboratory, CIPM, Portuguese Cancer Institute, 1099-023 Lisbon, Portugal.

Aneuploidy in papillary thyroid carcinomas (PTCs) is considered a marker of worse prognosis. Multiple genetic surveys have been performed in PTCs, however, we are not aware of any such studies in aneuploid PTCs. In order to contribute to a better comprehension of the genetic basis of this neoplasm’s more aggressive behaviour in 17 aneuploid PTCs we performed a comparative genomic hybridization (CGH) analysis, studied the BRAF and RAS mutational status, searched for RET/PTC1 and RET/PTC3 rearrangements and determined their expression profile. Array results were validated by TaqMan and immunohistochemistry. CGH revealed multiple non-random chromosomal abnormalities. BRAFV600E and RAS mutations were found in 41.2% and 33% of the carcinomas respectively. None of the studied cases presented RET/PTC1 or RET/PTC3 rearrangement. When comparing array data with the chromosomal, mutational and clinical data we found that: a) loss of control of cellular transcription was of major relevance in this group of neoplasms, HMGA2 being one of the most overexpressed genes; b) gene expression correlated with the mutational status of PTCs, as in BRAF+ cases cMET and FN1 were concomitantly overexpressed; and c) death from disease and distant metastasis was associated to the overexpression of DDR2 and to the down-regulation of genes involved in immune, inflammatory response, signal transduction and cell adhesion processes. In conclusion we have identified in aneuploid PTCs a group of significantly altered molecules that may represent preferential targets for the development of new more efficient therapies in this type of cancer.

30)  Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.  Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X. Department of General Surgery, Rush University Medical Center, Chicago, Illinois 60612, USA.

BACKGROUND: Anaplastic thyroid carcinoma (ATC) is the most lethal form of thyroid neoplasia and represents the end stage of thyroid tumor progression. In the current study, genetic alterations in a panel of ATC were profiled to determine the origins of ATC.

METHODS: Eight ATC were analyzed for BRAF mutation at codon 599 by using mutant-allele-specific polymerase chain reaction (PCR) and DNA sequencing of the PCR-amplified exon 15. RAS mutation (HRAS, KRAS, and NRAS) at codons 12, 13, and 61 was analyzed by direct sequencing of PCR-amplified exons 1 and 2 of the RAS gene. RET/PTC rearrangements and p53 mutation were monitored by immunohistochemical (IHC) staining by anti-RET antibodies and an anti-p53 mAb, respectively.

RESULTS: BRAF was mutated in 5 of the 8 ATCs tested. Histologic examination revealed that 4 of these 5 BRAF-mutated ATCs contained a PTC component, suggesting that they may be derived from BRAF-mutated PTC. Of the 3 ATCs with wild-type BRAF, 2 had spindle cell features; one had follicular neoplastic characteristics mixed with papillary structures. Analysis of RAS mutation revealed only an HRAS mutation at codon 11, due to the transversion of GCC to TCC in one ATC with wild-type BRAF. This leads to the substitution of valine to serine. IHC analysis of RET/PTC rearrangements revealed no positive staining of RET in any of 8 ATCs, suggesting that these ATCs are not derived from RET/PTC- rearranged PTC. In contrast, IHC analysis of p53 mutation revealed that p53 was detected in the nuclei of 5 of 5 BRAF-mutated ATCs and 2 of 3 ATCs with wild-type BRAF. p53 staining was present only in anaplastic thyroid tumor cells but not in neighboring papillary thyroid tumor cells.

CONCLUSIONS: These results suggest that many ATCs with papillary components are derived from BRAF-mutated PTC, because of the addition of p53 mutation.

31)  Anaplastic Thyroid Carcinoma Survival  Petri E. Voutilainen1, Markku Multanen1, Reijo K. Haapiainen1, Ari K. Leppäniemi1 and Arto H. Sivula1 Second Department of Surgery, Helsinki University Central Hospital, Box 260, FIN-00029 HUCH, Helsinki, Finland, FI

Abstract. Anaplastic thyroid carcinoma is a rare, highly malignant tumor of elderly people. The purpose of this retrospective study was to characterize the patient population and to detect a potential subgroup with better prognosis or any intervention that would be useful.

From 1967 through 1994 a total of 33 anaplastic thyroid carcinomas were operated on at the Second Department of Surgery, Helsinki University Central Hospital. There were 26 females and 7 males with mean age of 66.0 years (range 36–89 years). At the time of diagnosis 16 of 33 patients had distant metastases, and 32 of 33 of the tumors had invaded the thyroid capsule.

Disease-specific survival was 9.7% (95% confidence interval from 2.0% to 25.9%) at 1 year using the product limit survival analysis. In the stepwise Cox proportional hazards regression model, local resectability (p= 0.0002), presence of distant metastases at diagnosis (p= 0.0014), radiotherapy (p= 0.014), and radioiodine ablation (p= 0.039) were independent prognostic factors.

We concluded that even though statistically significant, independent, prognostic factors can be found the survival of the patients with the best prognostic characteristics is still poor. Only one patient, who had an anaplastic carcinoma focus within an encapsulated follicular thyroid carcinoma, survived in this series. At present there seems to be no surgical treatment that would be efficient for treating symptomatic anaplastic thyroid carcinoma.

32)  Surgery. 2001 Dec;130(6):1028-34. Anaplastic thyroid carcinoma: a 50-year experience at a single institution.  McIver B, Hay ID, Giuffrida DF, Dvorak CE, Grant CS, Thompson GB, van Heerden JA, Goellner JR. Department of Medicine, Mayo Clinic & Foundation, Rochester, MN 55905, USA.

BACKGROUND: Anaplastic thyroid carcinoma (ATC) is among the most aggressive of human malignancies. However, there have been few large studies of histologically well-defined ATC. We report the results of a 50-year experience of this lethal malignancy.

METHODS: We reviewed all cases of ATC managed in this institution between 1949 and 1999. One pathologist (J.R.G.) reviewed all pathologic material. Clinical details were obtained from medical records, and current status of all patients was determined. RESULTS: There were 134 cases, with a female-to-male ratio of 1.5:1 and a mean age of 67 years.

Benign thyroid disease was present in 27 cases (20%) and well-differentiated thyroid carcinoma in 31 (23%). Sixty-two patients (46%) had distant metastases at diagnosis, and 98% of the tumors were locally invasive. Primary treatment was surgical for 96 patients (72%). Complete resection was achieved in 29 cases (30%), with “minimal residual disease” in 25. Neither extent of operation nor completeness of resection affected survival (P > .4).

Postoperative radiotherapy gave slightly longer median survival (5 vs 3 months), which was not significant (P < .08). Multimodal therapy, including operation, chemotherapy, and radiotherapy, did not improve survival.

CONCLUSIONS: The outlook for patients with ATC remains grim. Novel treatments for ATC are desperately needed.

33) ATA News Release 2007. Small Papillary Thyroid Cancer Is More Common and Not Without Risk than Previously Believed

Oct. 5, 2007, 3:15 p.m. EDT— Patients with micropapillary thyroid cancer—small tumors equal to or less than 1 centimeter—and tumors even smaller, less than 1 millimeter (mm)—are more common and not without a risk as previously thought, according to a new study being presented on Fri., Oct. 5, at the 78th Annual Meeting of the American Thyroid Association (ATA) in New York.

This is contrary to the widely perceived belief that small papillary thyroid cancers are clinically insignificant and don’t require active treatment.

Papillary is the most common type of thyroid cancer, accounting for about 80% of all thyroid cancers.

The findings suggest that the size of the tumor itself may not be the sole determinant for the degree of the cancer’s aggressiveness. Small papillary cancer can indeed metastasize or spread to other parts of the body. Ten percent of patients in the study with micropapillary cancer and six percent of those with less than 1 mm cancers had tumors that spread to nearby lymph nodes in the neck.

“We would like to be appropriately aggressive in treating small aggressive cancers.  However, it is also important not to be aggressive in managing the majority of these patients with clinically insignificant small cancers. A better understanding of this disease will help us to better risk stratify these patients,” added Dr. Kuffner.

Total Thyroidectomy and RAI Do NOT improve outcome in MPC

34)   Papillary Thyroid Microcarcinoma -Do Total Thyroidectomy and/or Postoperative Radioiodine Improve the Outcome? By Mary Shomon, Updated: May 09, 2008

Researchers at the 10th European Congress of Endocrinology (ECE) reported on a new long-term follow-up study, which looked at the results of patients with papillary thyroid microcarcinoma.

The research, conducted out of the Mayo Clinic in Rochester, Minn., looked at approximately 900 papillary thyroid microcarcinoma patients from 1945 to 2004. The study looked at the impact various treatment approaches had on the risk of thyroid cancer recurrence and mortality, based on computerized data that had been maintained about the patient population. For example, some patients in the group received radioiodine remnant ablation.

The most important finding was that among 892 patients who had their thyroid tumors removed, none had any spread of the cancer during the 20 years after the surgery. The 20-year and 40-year recurrence rates for thyroid tumors were 6 and 9%.

Of the entire study population, only 3 patients (0.3%) died of papillary thyroid microcarcinoma, and the survival and mortality rates for the study group did not differ significantly from the control population. Interestingly, the risk of recurrence did not appear to be significantly improved by radioiodine remnant ablation treatment.

The researchers concluded that their findings confirm the following:

•Papillary thyroid microcarcinoma has an excellent prognosis if the primary tumor is completely removed during surgery.

•More than 99% of patients with papillary thyroid microcarcinoma are at no risk of a distant spread of the cancer or of dying of thyroid cancer.

•Neither total thyroidectomy (total surgical removal of the entire thyroid) nor postoperative radioiodine remnant ablation improved the patient outcome — risk of tumor recurrence or death from papillary thyroid cancer — over a 40-year period.


Papillary Thyroid Carcinoma -Grand Rounds Christopher Prichard, M.D. December 4, 2003

The ACS last year in their statistics reported 20,700 new cases a year with 1,300 deaths due to thyroid cancer. Thirty years ago there were about 8,000 new cases per year but the incidence of death has not increased significantly. At that time it was about 1,000 cases per year. If you look at an isolated thyroid nodule there is anywhere from 5% to 12% risk of development of cancer in an isolated nodule. Now, thyroid cancer in general is a variable disease and ranges from some of the best prognostic cancers that humans have to some of the most aggressive and deadly. We will see the 10-year survival rates show excellent survival rates for the well-differentiated cancers, papillary and follicular and terrible survival rates for anaplastic cancers.

In a study done in 1998, over 53,000 cases of thyroid cancer treated over a 10-year period in the U.S. were reviewed. This study found that between 77% and 81% in any given year were papillary thyroid cancers, the most common. The female to male ratio was 3:1, though the risk of dying from a papillary cancer is actually 2:1, males over females. The mean age of presentation in this study was 39 years and typically it presents in the third or fourth decade. These are indolent, slowly progressive tumors and there is an overall 10-year survival of 93%.

Most papillary cancers present as a clinically palpable asymptomatic nodule. Within a 40-year span, as many as 35% have recurrence after successful treatment. There is a high incidence of nodule metastasis: 35% of cases will have cervical node metastases, with the literature reporting this rate as high as 40 to 45%.

September 11, 2007  Thyroid Cancer Treatment May Be Overly Aggressive Reuters Health

37)  J Surg Res. 2006 Aug;134(2):160-2. Epub 2006 Jun 14.

What is the biology and optimal treatment for papillary microcarcinoma of the thyroid? Cheema Y, Olson S, Elson D, Chen H.Department of Surgery, Section of Endocrine Surgery, University of Wisconsin, Madison, WI 53792, USA.

BACKGROUND: Papillary microcarcinomas of the thyroid, defined as tumors measuring < or =10 mm, are believed to be a less aggressive subset of papillary cancers that behave more like benign lesions and are often more conservatively treated. However, some groups have reported a high incidence of metastases from papillary microcarcinomas and favor aggressive surgical resection followed by radioiodine therapy. Therefore, to characterize the biology and optimal treatment for papillary microcarcinomas, we reviewed our experience. METHODS: From May 1994 to October 2004, 184 patients underwent thyroid surgery at the University of Wisconsin and had papillary thyroid cancer present in the resected gland. Of these patients, 10 were excluded because there was no record of tumor size. Of the remaining 174 patients, 74 (42%) had papillary microcarcinomas. Data from these patients were retrospectively analyzed. RESULTS: The mean age of these patients was 42 +/- 1.48 year and 57 (77%) were female. The mean tumor size was 5.7 +/- 0.38 mm. Of the 74 patients, 12 (16%) had lymph node metastases. The majority of patients (65%) underwent a total thyroidectomy and 61% had radioiodine ablation therapy after surgery. With follow-up up to 134 months, the recurrence rate was 8% and only two patients currently have active disease. No patients with papillary microcarcinoma have died during this period.

CONCLUSION: Papillary microcarcinomas of the thyroid are quite common, comprising almost half of all papillary cancers. Despite a significant rate of metastatic disease, the prognosis for patients with microcarcinomas has been excellent with 100% survival and a low recurrence rate. These outcomes may be the result of the aggressive surgical therapy used at our institution. Thus, papillary microcarcinomas appear to have a similar biology to other low risk papillary thyroid cancers and, in our opinion, may warrant similar treatment.

Dr Ito – Japan

Expert Opin Pharmacother. 2007 Dec;8(18):3205-15. Appropriate treatment for asymptomatic papillary microcarcinoma of the thyroid. Ito Y, Miyauchi A.Kuma Hospital, Department of Surgery, 8-2-35, Shimoyamate-dori, Chuo-ku, Kobe 650-0011, Japan.

Since the 1990 s, asymptomatic papillary microcarcinoma (PMC), papillary carcinoma measuring <or= 1.0 cm, has frequently been detected using ultrasonographic screening and diagnosed by ultrasonography-guided fineneedle aspiration biopsy. Thyroid carcinoma was detected in 3.5% of otherwise healthy women aged >or= 30 years of age and most of these patients had lesions measuring <or= 1.5 cm in diameter, which is not discrepant with previous autopsy findings that latent PMC showed a high incidence. A recent observation trial showed that only 6.7% of low-risk PMC definitely became enlarged during 5 years of follow up, indicating that observation is an attractive alternative to surgery for PMC. However, PMC with clinically apparent metastasis detected on imaging is likely to show a recurrence to the lymph node and careful neck dissection as well as total thyroidectomy may be required. If surgical treatment is performed for low-risk PMC, prophylactic modified radical neck dissection is not necessary and lobectomy (with isthmectomy) and central node dissection is adequate if the tumor is located only in one lobe.

39)  Nat Clin Pract Endocrinol Metab. 2007 Mar;3(3):240-8. A therapeutic strategy for incidentally detected papillary microcarcinoma of the thyroid. Ito Y, Miyauchi A.Department of Surgery, Kuma Hospital, Kobe, Japan.

Papillary microcarcinoma of the thyroid (PMCT) is defined as papillary carcinoma measuring 1.0 cm or less. PCMT are frequently detected by ultrasonographic screening and ultrasonography-guided fine-needle aspiration biopsy. Although PMCT can pathologically show a high incidence of multifocality and lymph node metastasis in surgical specimens, most tumors grow slowly or not at all when they are monitored without surgery. In our observations only 6.7% of PMCT enlarged by 3.0 mm or more in diameter during 5 years of follow-up, and nodal metastases became detectable in 1.7% of patients overall. Observation without surgery could, therefore, be an attractive alternative for patients with low-risk PMCT; however, occult PMCT, which are diagnosed as the origin of lymph node or distant metastasis, show a worse prognosis. Even among incidentally detected PMCT, tumors with ultrasonographically detectable nodal metastasis are more likely to recur. Because such PMCT are most likely to recur in the regional lymph nodes, careful therapeutic neck dissection and total thyroidectomy are required. For incidentally detected and low-risk PMCT, careful observation without surgery might be acceptable, but careful and systematic surgery should be performed for patients with PMCT demonstrating aggressive characteristics.

40) Recent Advances in Thyroid Cancer Research 2006
Editors Yasuhiro Ito Akira Miyauchi Nobuyuki Amino Department of Surgery, Kuma Hospital 8-2-35, Shimoyamate-dori, Chuo-ku Kobe 650-0011, Japan

41)  Preoperative Ultrasonographic Examination for Lymph Node Metastasis: Usefulness when Designing Lymph Node Dissection for Papillary Microcarcinoma of the Thyroid

Yasuhiro Ito Department of Surgery, Kuma Hospital, 8-2-35 Shimoyamate-dori, Chuo-ku, 650-0011 Kobe, Japan April 2004

ABSTRACT Papillary microcarcinoma has an excellent prognosis after surgical treatment, but how to dissect the lymph nodes remains an open question. In this study, we investigated whether modified radical neck dissection (MND) affected the lymph node recurrence-free survival (LN-RFS) rate for 590 patients with papillary microcarcinoma and recurrence in the lateral compartment who underwent surgery in our hospital between 1993 and 2001. MND was performed in 316 patients, and metastasis in lateral compartment was preoperatively detected on ultrasonography in 67. These 67 patients showed significantly worse LN-RFS (p = 0.0038) than the remaining 249 patients without preoperatively detectable lateral node metastasis. Of the 523 patients (590 minus the 67 patients) whose lateral node metastasis was not detected preoperatively, 249 underwent MND; the remaining 274 patients did not. There was no significant difference in LN-RFS between these two groups. Our preliminary data suggest that with papillary microcarcinoma: (1) MND is not necessary in patients without lateral node metastasis detected on ultrasonography preoperatively, and (2) patients with preoperatively detected lateral node metastasis are more likely to develop recurrence in the lymph nodes so careful MND should be performed.

Papillary Microcarcinoma of the Thyroid: How Should It Be Treated?  Yasuhiro Ito Department of Surgery, Kuma Hospital, 8-2-35 Shimoyamate-dori, Chuo-ku, 650-0011 Kobe City, Japan October 2004

Abstract We previously demonstrated that (1) most papillary microcarcinomas can be followed without surgical treatment and (2) when surgery is performed, patients with lateral lymph node metastasis detected on preoperative ultrasonography (US) are more likely to develop recurrence. In this study, we further investigated the application of these strategies. To date, we have observed 211 patients (average follow-up 47.9 months). In more than 70% of these patients the tumor size did not increase during the follow-up period. There were no clinicopathologic features linked to tumor enlargement except in tumors 7 mm, which tended to enlarge in patients followed for 4 years.

To evaluate not only whether observation can continue but also how to dissect the lymph nodes optimally at surgery, US diagnosis for lateral node metastasis is essential because the presence of US-diagnosed lateral metastasis is an even stronger predictive marker for recurrence than the presence of pathologically confirmed node metastasis. The positive predictive value (PPV) was 80.6% for US but reached 100% if fine-needle aspiration biopsy (FNA of nodes or FNAB-thyroglobulin measurement is added. Furthermore, carcinomas occupying the upper region of the thyroid more frequently showed US-diagnosed and pathologically confirmed lateral metastasis, and those measuring 7 mm were more likely to show pathologically confirmed lateral metastasis. These findings suggest that, for papillary microcarcinoma: (1) US-diagnosed lateral metastasis is a strong marker predicting a worse relapse-free survival; (2) FNAB of nodes and FNAB-thyroglobulin measurement are useful tools for evaluating lymph node metastasis; and (3) careful US evaluation for lateral metastasis is necessary in patients with a tumor measuring 7 mm or that is located in the upper region of the thyroid both during observation and preoperatively.

43)  J Clin Pathol. 1991 March; 44(3): 205–207.  Occult papillary microcarcinoma of the thyroid–a potential pitfall of fine needle aspiration cytology?  H R Harach, E Saravia Day, and S B Zusman  Pathology Service, Dr A Onativia, Endocrinology and Metabolism Hospital, Salta, Argentina.

The use of fine needle aspiration cytology detected papillary carcinoma in two patients with multinodular goitre measuring 0.7 cm and 0.9 cm in diameter, respectively. Like most of the cases from previous large series, the tumours progressed slowly as shown by absence of enlarged glands on surgical exploration and no clinical signs of metastasis after two and five years of follow up. This study shows that aspiration cytology can detect a virtually harmless occult papillary carcinoma that will oblige patients to have surgery. This very occasional “pitfall” of fine needle aspiration should not preclude this well known beneficial method from being used in the management of thyroid disease.

Jeffrey Dach MD

Disclaimer click here:
The reader is advised to discuss the comments on these pages with
his/her personal physicians and to only act upon the advice of his/her personal physician. Also note that concerning an answer which appears as an electronically posted question, I am NOT creating a physician — patient relationship.
Although identities will remain confidential as much as possible, as I can not control the media, I can not take responsibility for any breaches of confidentiality that may occur.

Link to this article:

Copyright (c) 2009-2013 Jeffrey Dach MD All Rights Reserved
This article may be reproduced on the internet without permission, provided there is a link to this page and proper credit is given.

FAIR USE NOTICE: This site contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available in our efforts to advance understanding of issues of significance. We believe this constitutes a ‘fair use’ of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes.

  • Teril

    WOW! This is the most comprehensive complete set of studies on nodules and thyca I have ever come across! Well Done Dr Dach! I would love to share this on Inspire’s Thyca site… the patients who find their way there are so lost, upset, and confused. Once someone says the big C word, all they can think is get rid of it. I see a great many of people with Papillary Cancer seeming to have recurrences and multiple surgeries these days, or a tremendous amount of doctors playing it “safe”.

    I do find the increase of Follicular/Hurthle cell disturbing. I noticed there is little comment on Follicular and did not find any Hurthle cell noted. I know it’s supposed to be a less common cancer but having experienced it and now knowing a good many of others who have had it really makes me wonder if it is increasing. I know firsthand how an inconclusive FNA can be, with a simple “atypical cells present” statement. Not only ultrasounds but FNAs are challenging to make complete diagnosis. And to rush to remove such a critical gland and we know there is no way to replace it with synthetic drugs. There are so many factors that are left untreated that let to the nodules, cancer or not, that are never addressed!

    I was very grateful to be spared the RAI treatment and did a tracer dose of RAI after a Low Iodine Diet (LID) 2 things I will never do again as it is so damaging to remaining healthy tissue.. Further studying has shown me Hurthle cell does not uptake Iodine so my decision is cast in stone. I know I am a skeptic when it comes to traditional western medicine and it is my last resort; I do not have to be a rocket scientist to make conclusions based on my personal experiences and watching others suffer so terribly with quality of life after multiple surgeries, dissections and the permanent damage done through surgery and RAI and to remember it is quality of life and we all became terminal with our first breath.

    I am constantly amazed and wonder where and when will all this madness cease? The more science studies, the more it disproves itself… this is a wonderful well done comprehensive collection that truly does need to be shared with more people who are in the position of being level headed and explaining to patients to be clearly understood. That is NOT happening :(

    Thank you for all you do Dr Dach!

    • Hi Teril,

      Thanks for sharing your experience and your comments.

      warmest regards dr d

  • Diana Butler

    Thank you for such an extensive and seemingly exhaustive review of the literature on papillary carcinoma. As Teri above, I too have follicular carcinoma with hurthle cell and as she stated it is much more rare than the papillary variant. Teri referred me to your site and it is indeed impressive and I intend to read further!. I do have a couple of questions, if you please–

    .1. I would like to know if anyone has done an extensive review of the literature on our type of thyroid cancer and how we might access that. There seems to be so little written about it–at least that someone with my background can find without access to medical journals,

    2. How is the type of nodule determined to be papillary before surgery or FNA–it seems that nodules discussed in some of the articles cited in the review did not include total or partial thyroidectomy or biopsies–is it automatically assumed that nodules are papillary at the initial discovery?

    3. Am I correct to conclude from two of the articles that the incidence of follicular nodules was seen to be lessened with the introduction of iodine into the diet? (abstracts at ref 10 and 11),

    Thank you in advance for answering my questions. I hope they are posed in such a way that you can figure out what I need to know and understand more fully.

    • Follicular Thyroid Cancer has been controversial for many decades now, since it has an excellent prognosis. Because of this, a number of surgeons have advocated a more conservative approach to treatment for minimally invasive follicular thyroid cancer. Some will perform a lobectomy rather than complete throidectomy and consider radioactive iodine treatment unnecessary in this scenario. See these articles:
      J Clin Pathol. Mar 2007; 60(3): 244–250.
      Published online Jun 23, 2006. doi: 10.1136/jcp.2006.038604
      PMCID: PMC1860564
      Our approach to follicular-patterned lesions of the thyroid
      Zubair W Baloch and Virginia A LiVolsi
      Z W Baloch, V A LiVolsi, Department of Pathology and Laboratory Medicine, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, USA
      Correspondence to: Dr V A LiVolsi
      Department of Pathology and Laboratory Medicine, 6 Founders Pavilion, 3400 Spruce Street, University of Pennsylvania Medical Center, Philadelphia, PA 19104, USA;

      more references:
      Ann Surg Oncol. 2013 Mar;20(3):767-72. doi: 10.1245/s10434-012-2697-4. Epub 2012 Oct 31.
      Can minimally invasive follicular thyroid cancer be approached as a benign lesion?: a population-level analysis of survival among 1,200 patients.
      Goffredo P1, Cheung K, Roman SA, Sosa JA.
      Author information 1Division of General Surgery, Milano-Bicocca University, Monza, Italy.
      Minimally invasive follicular thyroid cancer (MIFC) is an encapsulated follicular tumor of low malignant potential. To date, histological criteria are still under debate, and there are no population-level data regarding characteristics and outcomes of patients with MIFC.
      METHODS:Patients diagnosed with MIFC in the Surveillance, Epidemiology, and End Results (SEER) database from 2000 to 2009 were included. Summary statistics were utilized to analyze patient characteristics; Kaplan-Meier analysis, and one-sample log-rank test were performed.
      RESULTS:A total of 1,200 patients with MIFC and 4,208 with widely invasive follicular thyroid cancer (WIFC) were identified over 10 years of follow-up. MIFC was more common than WIFC in younger patients (mean age 49 vs. 52.3 years; p < 0.001). More patients with MIFC were alive at the end of follow-up (96.8 vs. 86.5% WIFC; p < 0.001). Patients diagnosed with MIFC were less likely than those with WIFC to have lymph nodes involved and distant metastases (0.9 vs. 3.6% and 0.5 vs. 8.9%, respectively; both p < 0.001). Only 2 of 1,200 patients died of disease-specific causes; overall survival was comparable to the general US population (p = 0.16). Total thyroidectomy and RAI ablation were not associated with improvement in patient outcomes (p = 0.2 and 0.443, respectively). CONCLUSIONS:MIFC is associated with survival comparable to that of the normative US general population. Thyroid lobectomy alone may be considered adequate treatment in these patients.
      Chirurg. 2010 Jul;81(7):627-30, 632-5. doi: 10.1007/s00104-009-1884-8.
      [Minimally invasive follicular thyroid carcinoma : Not always total thyroidectomy].
      [Article in German]
      Hermann M1, Tonninger K, Kober F, Furtlehner EM, Schultheis A, Neuhold N.
      Author information 1Chirurgische Abteilung, Kaiserin-Elisabeth-Spital der Stadt Wien, Osterreich.
      Current treatment guidelines for follicular thyroid carcinoma (FTC) recommend total thyroidectomy, lymphadenectomy and radioiodine ablation. Considering the low malignant potential of minimally invasive follicular thyroid carcinoma (MIFTC), a limited radical therapeutic procedure may be adequate. MIFTC is an intensely discussed group of tumors and a review of the literature reveals disagreement among experts concerning the criteria for a distinct definition. Therefore, in 2005 Rosai proposed a clinically more significant classification of FTC based on the extent of capsular and vascular invasion: MIFTC with capsular invasion only, with limited (< or =3) vascular invasion, encapsulated FTC with extensive (>3) vascular invasion and broadly invasive FTC with extensive invasive growth.For the diagnosis of MIFTC a complete investigation of the encapsulated follicular lesion should be performed by the pathologist and examination of at least 10 tissue blocks is mandatory. Due to the excellent prognosis hemithyroidectomy constitutes an adequate therapeutic approach in MIFTC with capsular invasion only and may also be considered for MIFTC with limited vascular invasion. There are no indications for systematic lymphadenectomy.
      Thyroid. 2012 Aug;22(8):798-804. doi: 10.1089/thy.2012.0051.
      Outcomes and prognostic factors of 251 patients with minimally invasive follicular thyroid carcinoma.
      Sugino K1, Kameyama K, Ito K, Nagahama M, Kitagawa W, Shibuya H, Ohkuwa K, Yano Y, Uruno T, Akaishi J, Suzuki A, Masaki C, Ito K.
      Radioiodine ablation after total thyroidectomy is the generally accepted treatment for patients with widely invasive follicular thyroid carcinoma (FTC). The therapeutic strategy for minimally invasive FTC, on the other hand, is still a matter of controversy. The histological diagnosis of minimally invasive FTC is often made after lobectomy. The aim of this study was to determine the factors associated with the development of distant metastases in patients with minimally invasive FTC.
      METHODS:Between 1989 and 2006, 251 patients with minimally invasive FTC underwent initial surgery at our hospital. Their median follow-up period was 7.2 years. There were 194 women and 57 men. Their mean age at the time of surgery was 46 years. Distant metastases were diagnosed in 54 patients (21.5%). In 22 of them distant metastases were diagnosed at the time of the initial surgery (M1), and in the other 32 they were diagnosed during the follow-up period. Age at initial surgery, sex, primary tumor size, histological findings (differentiation, and extent of vascular and capsular invasion), completion total thyroidectomy, and distant metastases at initial surgery were assessed as prognostic factors for distant-metastases-free survival (DMFS) and cause-specific survival (CSS). The Kaplan-Meier method and log-rank test were used to analyze time-dependent variables. The Cox proportional hazard model was used to perform the multivariate analysis.
      RESULTS:Univariate analysis showed that age (45 years or older) and primary tumor size (4 cm or more) were significant prognostic factors related to postoperative distant metastases in the group of 229 patients without distant metastases at time of the initial surgery. The cumulative survival rate was significantly poorer in M1 patients, patients aged 45 years or older, and patients whose primary tumor size was 4 cm or more. Multivariate analysis showed that age was a significant prognostic factor both for DMFS and CSS.
      CONCLUSIONS:Age was the most powerful prognostic factor for patients with minimally invasive follicular thyroid cancer. The prognoses of patients younger than 45 years old were excellent and distant metastases rarely occurred. Routine completion total thyroidectomy and radioiodine ablation is thought unnecessary for these patients.

      Ann Surg Oncol. 1997 Jun;4(4):328-33.
      Low-risk differentiated thyroid cancer: the need for selective treatment.
      Shaha AR1, Shah JP, Loree TR.
      Author information 1Head and Neck Service, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
      The well recognized prognostic factors in differentiated carcinoma of the thyroid are age, grade, extracapsular extension, distant metastasis, and size of the tumor. Based on these prognostic factors, we have divided patients into low-, intermediate-, and high-risk categories. Clearly, there are significant differences in these three groups. This article analyzes in depth our data on low-risk thyroid cancer patients.
      METHODS:A retrospective review of 1,038 patients with differentiated carcinoma of the thyroid was undertaken. Various prognostic factors and risk groups were analyzed. Univariate and multivariate analyses were performed, and the survival curves were plotted by the Kaplan-Meier method. The inclusion criteria for the low-risk group were age younger than 45 years, tumors < 4 cm in size, low-grade histology, absence of distant metastasis, and absence of extrathyroidal extension. There were 465 patients in the low-risk group. Four hundred three patients had papillary and 62 patients had follicular thyroid cancer. There were 120 male and 354 female patients. Two hundred seventy-eight patients (60%) presented with clinically apparent lymph node metastasis. RESULTS:With a median follow-up of 20 years, the 10- and 20-year survival in this select group was 99%. The local, regional, and distant recurrence rates were 5, 9, and 2% in this series. The analysis of the data showed statistical difference in local recurrence rate between partial lobectomy and total lobectomy (27 vs. 4%; p = 0.005). There was no statistical difference in local recurrence rate between total lobectomy compared with total thyroidectomy (4 vs. 1%; p = 0.10). The overall failure rate between partial lobectomy and total thyroidectomy (27 vs. 8%) was statistically significant (p = 0.04). There was no statistical difference in the overall failure rate between total lobectomy and total thyroidectomy (13 vs. 8%; p = 0.06). There was no survival difference between various histologies or nodal status. CONCLUSIONS:Patients with low-risk tumors have excellent long-term survival. Nodulectomy or partial lobectomy should be avoided. The intraoperative decisions regarding the extent of thyroidectomy should be based on gross clinical findings and risk group analysis. Laryngoscope. 2004 Mar;114(3):393-402. Implications of prognostic factors and risk groups in the management of differentiated thyroid cancer. Shaha AR.Author information Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA. The outcome in differentiated thyroid cancer generally depends on the stage of the disease at the time of presentation; prognostic factors such as age, grade, size, extension, or distant metastasis; and risk groups (eg, low or high risk). The author has reviewed a large number of patients with differentiated thyroid cancer to analyze their hypothesis and to confirm that various risk groups have a major implication in relation to extent of the treatment and outcome. Differentiated thyroid cancers make up 90% of all thyroid tumors. The prognostic factors are well defined, such as age, size of the tumor, extrathyroidal extension, presence of distant metastasis, histological appearance, and grade of the tumor. The author has previously divided the risk groups into low-, intermediate-, and high-risk categories based on prognostic factors. The study describes the author's treatment approach related to the extent of thyroidectomy and adjuvant therapy based on various risk groups and the long-term survival. STUDY DESIGN: In a retrospective review of 1038 patients with differentiated thyroid carcinoma, various prognostic factors were studied by univariate and multivariate analysis. The significant prognostic factors were studied in detail and, based on these prognostic factors, the patients were divided into low-, intermediate- and high-risk groups. The survival curves were plotted by Kaplan-Meier method. The long-term survivals in low-, intermediate- and high-risk groups were 99%, 87%, and 57% respectively. Based on these risk groups, a decision tree was made regarding extent of thyroidectomy and adjuvant treatment. In the high-risk group and selected patients in the intermediate-risk group, aggressive surgery including removal of all gross disease and extrathyroidal extension with postoperative radioactive iodine ablation is recommended. In the low-risk group and selected patients in the intermediate-risk group, lobectomy appears to be satisfactory with excellent long-term outcome. The surgical treatment offers the best long-term results in low-risk patients, and the role of adjuvant treatment in this group is questionable. CONCLUSION: The decisions in the management of well-differentiated thyroid cancer should be based on various prognostic factors and risk groups. The long-term survival in the low-risk group is excellent, and consideration should be given to conservative surgical resection depending on the extent of the disease. In the high-risk group and selected patients in the intermediate-risk group, total thyroidectomy with radioactive ablation is warranted. A consideration may be given to external-beam radiation therapy in selected high-risk patients. It is apparent, based on the author's clinical experience and critical retrospective analysis, that the author's hypothesis that risk groups are extremely important in the long-term outcome of patients with differentiated thyroid cancer is correct. Based on various risk groups, the author currently is able to guide the treatment policies for thyroid cancer. Clin Oncol (R Coll Radiol). 2010 Aug;22(6):405-12. doi: 10.1016/j.clon.2010.03.009. Epub 2010 Apr 8. Management of thyroid nodules and surgery for differentiated thyroid cancer.Iyer NG1, Shaha AR. 1Head and Neck Service, Memorial Sloan-Kettering Cancer Center, New York 10065, USA. Abstract The incidence of well-differentiated thyroid cancer has seen a worldwide increase in the last three decades. Whether this is due to a 'true increase' in incidence or simply increased detection of otherwise subclinical disease remains unclear. The treatment of thyroid cancer revolves around appropriate surgical intervention, minimising complications and the use of adjuvant therapy in select circumstances. Prognostic features and risk stratification are crucial in determining the appropriate treatment. There continues to be considerable debate in several aspects of management in these patients. Level 1 evidence is lacking, and there are limited prospective data to direct therapy, hence limiting decision-making to retrospective analyses, treatment guidelines based on expert opinion and personal philosophies. This overview focuses on the major issues associated with the investigation of thyroid nodules and the extent of surgery. As overall survival in well-differentiated thyroid cancer exceeds 95%, it is important to reduce over-treating the large majority of patients, and focus limited resources on high-risk patients who require aggressive treatment and closer attention. The onus is on the physician to avoid treatment-related complications from thyroid surgery and to offer the most efficient and cost-effective therapeutic option. Medscape Medical News > Oncology Treatment Recommendations for Thyroid Cancer Need Reevaluation Roxanne Nelson November 24, 2010

      Is Lobectomy Enough?

      Is lobectomy sufficient? For some patients, the answer is yes, says Ashok R. Shaha, MD, from Memorial Sloan-Kettering Cancer Center in New York City, in an accompanying editorial.

      “The updated data from the Memorial Sloan-Kettering Cancer Center once again confirm our strong belief in lobectomy for patients with well-differentiated cancer in the low-risk category,” he writes.

      full pdf availabe–excellent aartcle

      Heffess, Clara S., and Lester DR Thompson. “Minimally invasive follicular thyroid carcinoma.” Endocrine pathology 12.4 (2001): 417-422.

      Minimally Invasive Follicular Thyroid Carcinoma
      Clara S. Heffess, MD and Lester D. R. Thompson, MD

      the distinction between a low-grade follicular
      carcinoma and a follicular adenoma
      is often made with great difficulty, uncer
      tainty, and frank disagreement among
      experts in thyroid pathology.

      We do not intend herein
      to extend the arguments on histologic
      interpretation of thyroid carcinoma, except
      to say that all attempts at classifying a
      disease must at times be arbitrary.

      FCMI will correctly predict the biologic
      behavior of the tumors in these patients;
      that is, they will not die from their disease
      nor will they develop metastatic disease
      with any appreciable degree of frequency.
      It can be argued that these tumors may then
      be considered benign if they do not develop
      metastases or cause the patient’s death. This
      brings us back to the definition of malignancy
      in the thyroid gland, or in other
      organs for that matter, and it is our position
      that infiltrative behavior is diagnostic
      of a carcinoma but should not imply a poor
      biologic outcome. Therefore, even though
      patients do not die from their disease or
      develop metastatic disease, we still believe
      that the term FCMI when applied strictly
      will allow the treating surgeon and endocrinologist
      to realize the low probability of
      disseminated disease and permit them to
      tailor the patients’ treatment to a lobectomy
      alone without additional surgery or
      adjuvant therapy.

      hope this helps.
      regards from dr d